EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas

Mescam, Lénaïg; Camus, Vincent; Schiano, Jean‐Marc; Adélaı̈de, José; Picquenot, Jean‐Michel; Guillé, Arnaud; Bannier, Marie; Ruminy, Philippe; Viailly, Pierre‐Julien; Jardin, Fabrice; Bouabdallah, Réda; Brenot-Rossi, I.; Bohers, Élodie; Robe, Cyrielle; Laurent, Camille; Birnbaum, Daniel; Wotherspoon, Andrew; Gaulard, Philippe; Xerri, Luc

doi:10.1182/blood.2019003408

Cited by 16 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This DLBCL is a lymphoid neoplasm frequently associated with EBV infection, initially described in Japan, and arises in the setting of longstanding chronic inflammatory process such as chronic osteomyelitis, pyothorax, metallic implant, or chronic skin ulcers [ 2 , 44 ]. Furthermore, it was also described in ileal neobladder, and related to breast implants [ 109 , 110 , 111 ]. The neoplastic cells have immunoblastic, centroblastic, or less commonly anaplastic features, with few nucleoli and limited to moderate amounts of cytoplasm.…”

Section: Dlbcl Associated With Chronic Inflammationmentioning

confidence: 99%

“…The immunoglobulin genes show clonal rearrangements and evidence of somatic hypermutation [ 2 , 112 ]. NGS in a series of chronic inflammation DLBCL associated with breast implant described mutations in genes known to be recurrently mutated in DLBCL, such as CREBBP, GNA13, TET2, IRF4, STAT3, and SOCS1 [ 110 ]. Latency III program is prevalent, since viral oncogenic antigens EBERs, LMP1, and EBNA-2 are positive in most cases, which may be related to the pathogenesis of this particular DLBCL subtype [ 44 , 111 ].…”

Section: Dlbcl Associated With Chronic Inflammationmentioning

confidence: 99%

See 1 more Smart Citation

Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma

Chabay

2021

Cancers

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin’s lymphoma (NHL) in adults. Epstein–Barr virus (EBV) positive DLBCL of the elderly was defined by the World Health Organization (WHO) in 2008, it was restricted only to patients older than 50 years old, and it was attributed to immunesenescence associated with physiological aging. After the description of EBV-associated DLBCL in children and young adults, the WHO redefined the definition, leading to the substitution of the modifier “elderly” with “not otherwise specified” (EBV + DLBCL, NOS) in the updated classification, and it is no more considered provisional. The incidence of EBV + DLBCL, NOS varies around the world, in particular influenced by the percentage of EBV+ cells used as cut-off to define a case as EBV-associated. EBV has effect on the genetic composition of tumor cells, on survival, and at the recruitment of immune cells at the microenvironment. In this review, the role of EBV in the pathogenesis of DLBCL is discussed.

show abstract

Section: Dlbcl Associated With Chronic Inflammationmentioning

confidence: 99%

Section: Dlbcl Associated With Chronic Inflammationmentioning

confidence: 99%

Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma

Chabay

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…1 Although BIA-ALCL is the most frequent large-cell lymphoma related to BIs, DLBCL-ACI may also occur in a similar clinical setting, albeit rarely. 2,3 The initial misdiagnosis in this case was probably related to multiple factors, mainly due to lack of awareness of DLBCL-ACI/FA-DLBCL in relation to BIs and the assumption that a CD30-positive large-cell lymphoma occurring in this setting is (by default) BIA-ALCL. Extensive infarction resulted in suboptimal immunostaining, with heavy smearing artefact hindering interpretation.…”

Section: Commentmentioning

confidence: 97%

“…2,3 The neoplastic cells in most previously reported cases have been limited to fibrinous material and the periprosthetic fibrous capsule, with no extracapsular spread or mass formation. An EBV latency pattern III with coexpression of EBV-LMP1 and EBNA2, which has been reported in most of these cases 2,3 and in FA-DLBCL involving a variety of sites, 6 was also seen in our case. The favourable outcome observed on follow-up has given rise to some debate, with increasing evidence suggesting that such cases are better classified as FA-DLBCL.…”

Section: Commentmentioning

confidence: 99%

Fibrin‐associated diffuse large B‐cell lymphoma misdiagnosed as breast implant‐associated anaplastic large‐cell lymphoma

et al. 2021

View full text Add to dashboard Cite

“…The pathologic and molecular features confirmed EBV-positive diffuse large B-cell lymphoma, activated B-cell subtype. [29][30][31][32][33]…”

Section: Pathologymentioning

confidence: 99%

Breast Implant-associated Anaplastic Large Cell Lymphoma

Alotaibi

Hamadani

Al‐Μansour

et al. 2021

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon lymphoproliferative disorder, mainly associated with textured implants. The average time from the breast implants to the development of BIA-ALCL is about 7 to 10 years, and the median age at the time of diagnosis is in the mid-50s. The exact incidence and prevalence of BIA-ALCL are not known. The pathogenesis of BIA-ALCL remains unclear. Different theories have been postulated, including immune response to textured implants, subclinical bacterial infection, and genetic predisposition. However, none of those theories have yet been proven to be causal in the pathogenesis of BIA-ALCL. BIA-ALCL is histologically similar to but clinically distinct from other CD30-positive T-cell lymphomas such as anaplastic lymphoma kinase-positive, anaplastic lymphoma kinase-negative, and primary cutaneous ALCL. The revised World Health Organization classification of lymphoid neoplasm in 2016 recognized BIA-ALCL as a provisional entity. Suspected cases need proper evaluation and workup to confirm the diagnosis. Surgical resection should be considered for all the cases. However, adjuvant radiotherapy and anthracycline-based chemotherapy are warranted for locally advanced and advanced cases.

show abstract

EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas

Cited by 16 publications

References 24 publications

Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma

Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma

Fibrin‐associated diffuse large B‐cell lymphoma misdiagnosed as breast implant‐associated anaplastic large‐cell lymphoma

Breast Implant-associated Anaplastic Large Cell Lymphoma

Contact Info

Product

Resources

About